HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note published on Monday,Benzinga reports. They currently have a $10.00 price target on the biopharmaceutical company’s stock.
A number of other research firms have also recently commented on SGMO. Barclays upped their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Truist Financial decreased their price target on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Jefferies Financial Group decreased their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, December 31st. Finally, Wells Fargo & Company dropped their price target on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 31st. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $5.17.
Check Out Our Latest Research Report on Sangamo Therapeutics
Sangamo Therapeutics Stock Down 2.6 %
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.07. The firm had revenue of $49.41 million during the quarter, compared to analysts’ expectations of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period last year, the business earned ($0.34) earnings per share. As a group, equities analysts anticipate that Sangamo Therapeutics will post -0.47 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Sangamo Therapeutics
Several institutional investors have recently bought and sold shares of SGMO. Renaissance Technologies LLC boosted its stake in shares of Sangamo Therapeutics by 58.8% in the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after purchasing an additional 1,528,600 shares during the period. Marshall Wace LLP lifted its holdings in Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 207,476 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Sangamo Therapeutics in the 2nd quarter valued at approximately $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Sangamo Therapeutics in the second quarter worth $89,000. Finally, Vontobel Holding Ltd. increased its position in shares of Sangamo Therapeutics by 412.3% during the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock worth $259,000 after acquiring an additional 241,440 shares during the period. 56.93% of the stock is owned by institutional investors and hedge funds.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Further Reading
- Five stocks we like better than Sangamo Therapeutics
- How to Calculate Options Profits
- Sizing Up a New Opportunity for NVIDIA Investors
- What Makes a Stock a Good Dividend Stock?
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Are Penny Stocks a Good Fit for Your Portfolio?
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.